Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
Titel:
Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
Auteur:
Lonardi, S. Andre, T. Wong, K.Y.M. Morse, M. McDermott, R. Hill, A. Hendlisz, A. Lenz, H. Leach, J. Moss, R.A. Cao, Z.A. Ledeine, J. Kopetz, S. Overman, M.